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Abstract
Background: Peripheral arterial disease (PAD) affects more than 200 million of the global population. PAD
represents a marker for premature cardiovascular events. Patients with PAD, even in the absence of a history of
myocardial infarction or ischemic stroke, have approximately the same relative risk of death from cardiovascular
causes as patients with a history of coronary or cerebrovascular disease. Despite the high prevalence of PAD and
the strong association with cardiovascular morbidity and mortality, patients with PAD are less likely to receive
appropriate treatment for their atherosclerotic risk factors than those who are being treated for coronary artery
disease.
Atherosclerotic risk factor identification and modification play an important role in reducing the number of adverse
outcomes among patients with atherosclerosis. Risk reduction therapy decreases the risk of cardiovascular mortality
and morbidity in patients with PAD. In this study, we aim to evaluate the effectiveness of a lifestyle and risk factor
modification intervention programme in achieving treatment goals for PAD risk factors.
Methods: This is a randomised, parallel group, active-control trial to compare the effectiveness of the risk factor
modification intervention programme to standard healthcare in a tertiary vascular care centre, in the reduction of
modified risk factors in PAD patients. The primary outcome of this study is to evaluate the effectiveness of a lifestyle
and risk factor modification intervention programme in achieving treatment goals for PAD risk factors at 3 and 12
months. The secondary outcomes are to compare the impact of the programme on clinical outcomes in PAD
patients at 12 months. Secondary outcomes include amputation-free survival, clinical improvement, haemodynamic
improvement, need for revascularisation procedures, outcomes of revascularisation procedures, changes in quality
of life and the incidence of adverse events.
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Discussion: This study will provide clear evidence on the effectiveness of a lifestyle and risk factor modification
intervention programme in achieving treatment goals for PAD risk factors, through a high-quality, well-powered
clinical trial.
Trial registration: This trial was registered (11/07/2017) on the European Clinical Trials Database (EudraCT number
2017-002964-41) and ClinicalTrials.gov (NCT03935776) which was registered on 02 May 2019.
Keywords: Peripheral arterial disease, PAD, Atherosclerosis, Risk factors, Lifestyle and risk factor modification
intervention programme, Randomised controlled trial
Background
Peripheral arterial disease (PAD) affects more than 200
million of the global population [1]. PAD represents a
marker for premature cardiovascular events [2]. Patients
with PAD, even in the absence of a history of myocardial
infarction or ischemic stroke, have approximately the
same relative risk of death from cardiovascular causes as
patients with a history of coronary or cerebrovascular
disease [2]. Despite the high prevalence of PAD and the
strong association with cardiovascular morbidity and
mortality, patients with PAD are less likely to receive ap-
propriate treatment for their atherosclerotic risk factors
than those who are being treated for coronary artery
disease [3, 4].
As PAD represents a peripheral manifestation of ath-
erosclerosis, most traditional and novel cardiovascular
risk factors are strongly associated with this condition
[5–7]. Smoking, diabetes, hyperlipidaemia, hypertension,
unhealthy diet and physical inactivity were identified as
significant modifiable risk factors that should be targeted
for secondary prevention [8–12].
Atherosclerotic risk factor identification and modifi-
cation play an important role in reducing the number
of adverse outcomes among patients with atheroscler-
osis [13]. Risk reduction therapy decreases the risk of
cardiovascular mortality and morbidity in patients
with PAD [13]. Because of the efficacy of these tech-
niques, several expert committees have recommended
their use in patients with PAD [8–12]. Despite clear
guidelines, several studies have shown that patients
with PAD are routinely undertreated for these risk
factors [4], which may contribute to high rates of
morbidity and mortality.
Previous studies concluded that modifiable risk factor
programmes help cardiac patients achieve their risk fac-
tor modification targets, with subsequent reduction in
cardiovascular events [14–16]. To our knowledge, cur-
rently, there is still no evidence to support that the im-
plementation of a structured modifiable risk factor
reduction program will lead to improved outcomes in
PAD patients. However, due to the similar atheroscler-
otic burden in cardiac and PAD patients, we hypothesise
that these risk factor modification programmes would
similarly improve risk factor target achievement in PAD
patients and subsequently improve their clinical out-
comes and reduce their amputation rates when com-
pared to standard healthcare.
The possibility of lifestyle and risk factor modification
intervention should have a positive impact on patients’
clinical well-being and on their quality of life.
Study objectives
Primary objective
The primary objective of this study is to evaluate the
effectiveness of a lifestyle and risk factor modification
intervention programme in achieving treatment goals for
PAD risk factors compared to the standard healthcare
management.
Secondary objectives
Secondary objectives are to compare the impact of the
programme on clinical outcomes in PAD patients,
specifically:
 Amputation-free survival
 Clinical improvement [17]
 Haemodynamic improvement [17]
 Need for revascularisation procedures
 Changes in quality of life [18]
 The incidence of adverse events
Methods
Study design
This is a randomised, parallel group, active-control trial
to compare the effectiveness of the risk factor modifica-
tion intervention programme to standard healthcare in a
tertiary vascular care centre, in the reduction of the
prevalence of modifiable risk factors in PAD patients.
This trial will randomise patients with PAD in an
equal ratio to one of two treatment arms. One arm will
be randomised to undergo a risk factor modification
intervention programme at a community-based centre.
The other arm will be provided with standard healthcare
advice, in the outpatient PAD clinic in a tertiary referral
vascular centre. Patients randomised into the risk factor
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modification intervention programme will have the
intervention administered for 12 weeks. Patients will
then be followed for 12 months to determine further
PAD outcomes. The participant flowchart through the
study is shown in Fig. 1. SPIRIT figure for this trial is
given in Fig. 2.
Study setting
Potential participants will be identified from the out-
patient PAD clinic at the University Hospital Galway,
Ireland (UHG). Patients will be screened and rando-
mised at the outpatient PAD clinic in UHG.
The risk factor modification intervention
programme will be administered in a nurse-led
community-based centre (Croí Heart and Stroke
Centre, Galway, Ireland), in the presence of a physio-
therapist and dietitian. The control arm will be man-
aged in the outpatient PAD clinic, UHG. The
coordinating centre will be the Department of Vascu-
lar and Endovascular Surgery, UHG, and the School
Fig. 1 Participant flowchart through the study
Elfghi et al. Trials          (2021) 22:138 Page 3 of 10
of Medicine at the National University of Ireland Gal-
way (NUI Galway). Patients are directly supervised
during the intervention. The 12-week and 1-year as-




 Aged 18 years or more
 Provide written informed consent
Fig. 2 SPIRIT figure showing an overview of the assessment schedule at baseline and follow-up in study. ABI: ankle-brachial Index, WIfI: wound
ischaemia and foot infection classification, HbA1c: glycosylated haemoglobin, BMI: body mass index, HADS: Hospital Anxiety and Depression
Scale, MACE: major adverse cardiovascular event and MALE: major adverse limb event
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 PAD: diagnosed by at least one of the following:
– Ankle-brachial index of less than 0.90 in at least
one lower extremity [9]
– Toe brachial index of less than 0.60 [9]
– Evidence of arterial occlusive disease in one lower
extremity detected by duplex ultrasonography,
computed tomographic angiography, or magnetic
resonance angiography [9]
 Symptomatic PAD (Rutherford category 2 and above
[19])
 Patients should have at least one of the following
risk factors:
– Blood pressure > 140/80 mmHg
– Fasting blood sugar (FBS) > 53 mmol/mol
– Glycosylated haemoglobin (HbA1c) > 7%
– Total cholesterol > 5 mmol/L
– Low-density lipoprotein (LDL) cholesterol > 2.6
mmol/L
– Triglycerides > 1.7 mmol/L
– High-density lipoprotein (HDL) < 1.0 mmol/L in
men and < 1.2 mmol/L in women
– Physical activity less 30 min for 5 days per week
– Body mass index (BMI) > 25 kg/m2
– Waist circumference > 80 cm in women, and > 94
cm in men
– Current smoker or exposure to tobacco in any
form
– Unhealthy diet, Mediterranean diet score less
than 10 points
Exclusion criteria
 Involvement in another clinical trial in the previous
6 months
 Legal incapacity
 Inadequate English language ability to understand
the content of the intervention programme
 Significant cognitive impairment or mental illness
 Refusal to participate in a certain part of the
intervention
 Patient suffering from a comorbidity that could
affect either their physical participation in the
intervention arm or influence outcomes (e.g.
ischemic heart failure or severe chronic kidney
disease with an estimated glomerular filtration rate
of less than 30mL/min [20])
 Patient is immobile
 Contraindication to anticoagulation and antiplatelet
medications or any of the risk factors treatment.
Study screening
Patients with Symptomatic PAD (Rutherford category 2
and above [19]) will be invited to join the study. Invited
patients will be provided with a pre-designed informa-
tion leaflet. This leaflet will be fully explained to the
patient at the initial assessment. The study re-
searchers will answer any questions about the study.
Informed consent will be obtained from the patient
on a formatted consent form. Patients will be given
the freedom to give consent either on the same day
or at a later date in accordance with a study within a
trial (SWAT), entitled “Same-day Consent vs Delayed
Consent in a Randomised Trial: A Study within a
Trial” [21]. This SWAT aims to ensure the rigorous-
ness of the consent process and will run in conjunc-
tion with this randomised controlled trial.
Researchers will screen the patient for inclusion and
exclusion criteria and administer a series of the
following:
1. Record PAD risk factors such as smoking,
hyperlipidaemia, diabetes, hypertension, increased
body weight and the patient’s current medication.
2. Document the Rutherford category [19],
claudication distance and absolute walking distance
for each patient, to assess the severity of PAD.
3. Schedule appointments for baseline health
assessments over the following month.
Randomisation
After meeting the inclusion criteria, screened patients
will be randomised to one of two treatment arms. One
arm will receive the 12-week intensive risk factor modifi-
cation intervention programme. The control arm will be
provided with standard care in the outpatient PAD
clinic. This is an intention to treat designed study, where
patients are analysed as randomised. Each screened pa-
tient will be given a unique screening number.
Screened patients will be randomised in a 1:1 ratio of
study intervention: control according to a randomisation
scheme. The randomisation scheme will be produced
using the PROC PLAN® procedure of the SAS®software
package (version 9.2.2) using a simple randomisation
strategy. The scheme will be concealed from all patients
and study personnel until after database lock.
Patients will be allocated to intervention via an auto-
mated telephone system, which will not deliver the ran-
domised allocation except after registering the subject
screening number. Each screened patient who is re-
cruited to the trial will be given a unique patient trial
number.
The statistician will remain blinded to the treatment
allocation until all the data have been analysed to min-
imise bias. Outcome assessors and data analysts will be
blinded; however, in the event of an adverse event out-
come, assessors will be unblinded.
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Baseline, prior to intervention
All randomised patients will undergo a full baseline as-
sessment prior to their intervention:
1. PAD assessment;
a. Ankle-brachial index (ABI)
b. Digital pressure
c. Rutherford category [19]
d. Wound ischaemia and foot infection
classification (WIfI) [22]
2. Blood samples including:
a. Fasting blood lipids
b. Fasting glucose
c. HbA1c
3. Blood pressure documentation
4. Anthropometric measurements including:
a. BMI
b. Waist circumference
5. Sub-maximal functional capacity exercise testing
including:
a. Shuttle test [23]
b. Claudication distance [24]
c. Absolute walking distance [25]
6. Behavioural and psychological survey using the
Hospital Anxiety and Depression Scale (HADS)
[26].
7. Health-related quality of life assessment: Dartmouth
Quality of Life score [18].
8. Smoking status assessment using the Fagerstrom
Test for Nicotine Dependence [27].
9. Physical activity assessment: Godin and Shepard
Leisure Exercise Questionnaire [28].
10. Nutritional assessment through the Mediterranean
Diet Questionnaire [29].
Intervention
Risk factor modification structured Programme
The risk factor modification intervention programme is
a 12-week intensive lifestyle programme. This is a nurse-
led, community-based, lifestyle and risk factor modifica-
tion intervention modelled on the European Society of
Cardiology demonstration project, a large clinical trial
called EuroAction [30]. The programme includes:
 Phase 1: Initial individualised assessment by the
multidisciplinary team (MDT) will include
previously mentioned baseline assessment in
addition to the following:
– Dietician will assess, current eating habits and
food diary
– Exercise specialist will assess 7-day activity recall,
barriers to exercise, 7-day pedometer and Func-
tional Capacity Test
 Phase 2: The intervention including:
– Weekly exercise class and educational workshops.
– Serial blood pressure, body mass index, waist
circumference, glucose and lipid measurements
with goal setting.
– Weekly MDT meetings.
– Targeted and protocol-based pharmacotherapy to
support lifestyle changes.
Standard healthcare
The control group will receive the standard healthcare
advice provided to PAD patients in the outpatient PAD
clinic. In this study, standard care will be conducted by
the researchers which include:
 Advising patients to quit smoking, regular exercise
and healthy eating, but neither structured
intervention nor organised cessation plans will be
addressed.
 Non-specific interventions, such as providing
patients with educational material on general health
problems.
Twelve-week assessment
On completion of the 12 weeks in both groups, patients
are reassessed for risk factors, therapeutic management
and lifestyle changes similar to baseline.
One-year assessment
Similar to the baseline and 12-week assessment, in
addition to clinical outcomes assessment, the following
are included:
1. If the patient underwent a major amputation and
level of amputation
2. If required a revascularisation procedure.
3. Any residual stenosis of more than 30% [17]
4. If developed a major adverse cardiovascular event
(MACE) or major adverse limb event (MALE)
5. Health-related quality of life
6. Cost-effectiveness of the programme
Endpoints
Primary endpoint
Achieving target improvement in lifestyle risk factors at
12 weeks and at 1 year. Target improvement will be con-
sidered if the patient achieves any one or more of the
following:
1. Smoking cessation
2. BMI 20–25 (kg/m^2). BMI is calculated by dividing
body weight in kilogrammes by the square of height
in meters
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3. HbA1c less than 7%
4. Total cholesterol less than 5.0 mmol/L
Patients will be reassessed for the primary endpoint at
1 year. If they fail the criteria by which they were
deemed at 12 weeks to have achieved the primary end-
point, they will then be considered to not have achieved
the 1-year primary endpoint.
We will report the primary endpoint for both time
points.
Secondary endpoints
Secondary endpoints of PAD outcomes are based on the
Society for Vascular Surgery (SVS) reporting standards
[17]:
1. Amputation-free survival; defined as time spent free
from any major above ankle amputation [17]
2. Hemodynamic improvement: defined as an increase
in the ABI by at least 0.10 [17]
3. Clinical improvement: which is defined as an
upward shift by at least one Rutherford category.
However, PAD patients suffering from actual tissue
loss (Rutherford category 5 [19]) should move up
two Rutherford categories to be considered
improved [19].
4. Re-intervention or stenosis rate; any re-intervention
or stenosis among patients who already underwent
vascular surgery [17]
5. Freedom from major adverse cardiovascular events
(MACE). MACE is defined as any major
cardiovascular event such as myocardial infarction,
cerebrovascular accident or death [17].
6. Major adverse limb events (MALE). MALE is
defined as any major amputation or
revascularization procedure [17].
7. Revascularisation-free survival; defined as time free
from any revascularisation procedure regardless of
if it were an endovascular intervention or an open
surgery [17].
8. Change from baseline of the following risk factors:
a- BMI (measured in kg/m2)
b- HbA1c (measured as a percentage)
c- Total cholesterol (measured in mmol/L)
9. Health-related quality of life [18]; assessed using the
Dartmouth Cooperative Information Project
(COOP) charts at enrolment and after 1 year. The
COOP charts measure six core aspects of functional
status: physical fitness, feelings, daily activities,
social activities, change in health, pain, and overall
health. The instrument consists of six charts,
referring to the abovementioned aspects of
functioning. Each chart consists of a simple title, a
question referring to the status of the patient and
an ordinal 5-point response scale illustrated with a
simple drawing. Each item is rated on this 5-point
ordinal scale ranging from 1 (no limitation at all) to
5 (severely limited); for “change in health” score 1
means “much better” and score 5 “much worse”.
The designers do not advocate summing the re-
sponses to gain a single index figure of health status
Safety endpoints
1. Incidence and severity of adverse events
2. Incidence of side effects due to medication
commenced during the trial, for the modulation of
any PAD risk factor. This includes any drug
interaction of these medications with any previously
assumed medication the patient was using regularly
prior to commencing the trial.
Sample size calculation
For sample size calculation, the EUROACTION study
[30] was used to estimate the coefficient of variation for
sample proportions.
Data from the EUROACTION [30] study suggest that
12-week intervention response rates for the primary
endpoint of 54.8% (intervention programme) and 35.6%
(usual care). Eighty percent statistical power and an
alpha level of 5% were chosen. A two-sample compari-
son of proportions sample size calculation was
implemented.
With these parameters, the G*Power [31] software
yields a trial with a maximum sample size of 208 pa-
tients completing the intervention (104 per intervention
group).
Statistical analysis
All data will be analysed according to the intention to
treat principle. The primary outcome, the achievement
of treatment goals for PAD risk factors between both
groups at 12 weeks and 12months will be compared
using chi-square or Fisher’s exact where appropriate.
Secondary outcomes including time to event will be
assessed using Kaplan-Meier survival curves and log
rank test. An exact 95% confidence interval will be ap-
plied for the difference between intervention groups in
terms of PAD risk factor reduction.
Discussion
PAD is a very common disease that affects the quality of
life of a large segment of the global population [1].
While PAD has been associated with increased risk of
cardiovascular events, yet most recommendations for
risk factor modulation in this population has been based
mainly on studies on patients with cardiovascular disease
[14–16, 32].
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These recommendations for lifestyle modification
techniques in PAD patients have included smoking ces-
sation based on level 1B evidence and healthy diet and
physical activity based on level 1C evidence [12]. How-
ever, none of these recommendations was based on ran-
domised clinical trials. In fact, the recommendation for
smoking cessation in PAD patients was based on obser-
vational studies that noted that smokers had a seven-
fold increased risk of developing PAD [33, 34] and a
two-fold higher risk of amputation [35]. There are no
randomised controlled trials that have quantified the dir-
ect effect of smoking cessation, directly targeting this
specific PAD population.
It is worth noting that most PAD patients have multi-
factorial risk factors. This adds to the limitations of any
study designed to target risk factor modulation. Studies
designed with a single risk factor treatment approach
have the potential to fail, due to the confounding effects
of other risk factors. Alternatively, in a study like our
proposed trial, where a full multi-risk factor improve-
ment approach is adopted, it is difficult to assess, which
particular intervention yielded the best outcome.
In a multifactorial risk factor modification programme,
some of the risk factors, like blood pressure, blood tests,
anthropometrics and exercise testing assessments, are
easily assessed with objective measurement tools. How-
ever, certain aspects can only be assessed using subject-
ive methods like the HADS [26], Dartmouth Quality of
Life score [18], Fagerstrom Test for Nicotine Depend-
ence [27] and Mediterranean Diet Questionnaire [29].
This is a potential limitation of this study, due to the in-
herent bias of patients responding to such subjective
questionnaires.
It has been shown that patients with PAD are rou-
tinely undertreated for most risk factors [4], which may
contribute to high rates of morbidity and mortality.
However, in the absence of level 1 evidence to support
its implementation in this particular cohort of patients,
it could be difficult to convince health authorities of the
benefits of spending on such programmes. Cost of pro-
viding a multifactorial risk factor modification
programme to all PAD patients could be prohibitive.
However, if proven to be effective and included in the
guidelines of management of PAD patients, this added
cost should be weighed against the potential benefits
and long-term savings of reducing cardiovascular events.
We aim with this study to provide clear evidence for the
effectiveness of a lifestyle and risk factor modification
intervention programme in achieving treatment goals for
PAD risk factors, through a high-quality, well-powered
clinical trial.
Any important protocol modifications will be commu-
nicated first to the REC. Following ethical approval, an
amended patient information leaflet will be circulated to
trial participants. The trial registries and journal will be
notified of the amended protocol.
Trial registration
This trial was registered (11/07/2017) on the European
Clinical Trials Database (EudraCT number 2017-
002964-41) and ClinicalTrials.gov (NCT03935776)
which was registered on 02 May 2019. Additional file 1;
Section 1, shows Trial Registration Data Set.
Trial status
The study is ongoing at the time of submitting this
manuscript (November 2019). This trial was using
protocol version 2.0 (14 March 2018) at the time of this
submission. Recruitment started in the University Col-
lege Hospital, Galway, Ireland on 1 June 2018 and is ex-
pected to be completed on 1 June 2021. The trial
management committee manages and disseminates the
protocol amendments.
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